Naura Technology (002371 CH)

3Q earnings: Strong orders, supply constrained

NAURA reported 3Q26 revenue of RMB11.3bn (+1.3% YoY/14.9% QoQ) and net profit of RMB2.0bn (+5.2% YoY/16.5% QoQ). The YoY deceleration in revenue (2Q26 growth: +24% YoY) reflected material shortages in select product categories as mgmt. noted that orders continued to grow and shipments increased significantly, suggesting that delivery constraints, rather than demand weakness, were the main bottleneck. GPM fell 2.0ppts YoY and 1.0ppt QoQ to 38.3% in 3Q26, reflecting higher component iteration and upgrade costs during new-product validation and discounts for certain high-volume customers. Maintain BUY. As China’s leading platform-based semi manufacturing equipment supplier, NAURA remains a key beneficiary of the structural localization of the SPE sector. We trim our TP to RMB750 based on 50x 2027E P/E (52x prev.), slightly above its one-year historical forward average of 48x.

 Order momentum remains firm, but material availability is constraining delivery. AI-related semi demand, domestic capacity expansion and equipment localization continued to support market-share gains across etching, thin-film deposition, thermal processing, wet cleaning, ion implantation, track and bonding equipment in 9M26. Mgmt. noted continued order growth and a significant increase in shipments, although shortages of certain materials limited revenue conversion. Inventory rose 11.1% QoQ to RMB33.9bn by 3Q26, while contract liabilities remained broadly stable at RMB5.3bn. The inventory build supports future deliveries but highlights the importance of supply-chain execution and customer acceptance. We lower our FY26E/27E revenue forecasts by 4.1%/2.3%.

Higher R&D investment and GPM pressure continued to constrain operating leverage. In 9M26, R&D expenses increased 17.2% YoY to RMB3.85bn, while selling expenses rose 41.4% to RMB1.21bn as NAURA expanded its market-development and customer-service resources. Meanwhile, 9M26 GPM declined 2.0ppts YoY to 39.4%, mainly due to higher component iteration and upgrade costs during new-product validation and commercial discounts for selected high-volume customers. Accordingly, we reduce our FY26E/27E GPM assumptions by 0.1ppt/0.4ppt.

 Revenue visibility remains solid, with execution and margin recovery now the key variables. NAURA’s broad product portfolio, growing order base and increasing process coverage should support its medium-term outlook. Near-term performance will however depend on improved material availability, faster product validation and customer acceptance. Key risks include prolonged supply-chain constraints, slower customer acceptance, intensifying price competition, etc.

Earnings Summary Aaron GUO

Source: Company data, Bloomberg, CMBIGM estimates

BUY (Maintain)

Target Price RMB750.00

(Previous TP RMB814.00)

Up/Downside 56.7%

Current Price RMB478.74

China Semiconductors

Zhimin ZHOU (852) 3850 5268 zhouzhimin@cmbi.com.hk

Kevin ZHANG

(852) 3761 8727 kevinzhang@cmbi.com.hk

(852) 3916 3715 aaronguo@cmbi.com.hk

Stock Data

Shareholding Structure Share Performance

Source: FactSet

Figure 1: Earnings revision

Source: Company data, CMBIGM estimates

Figure 2: CMBIGM estimates vs. BBG consensus

Source: Bloomberg consensus, CMBIGM estimates

Financial Summary

Source: Company data, CMBIGM estimates. Note: The calculation of net cash includes financial assets.

Disclosures & Disclaimers

Analyst Certification

The research analyst who is primary responsible for the content of this research report, in whole or in part, certifies that with respect to the securities or issuer that the analyst covered in this report: (1) all of the views expressed accurately reflect his or her personal views about the subject securities or issuer; and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific views expressed by that analyst in this report. Besides, the analyst confirms that neither the analyst nor his/her associates (as defined in the code of conduct issued by The Hong Kong Securities and Futures Commission) (1) have dealt in or traded in the stock(s) covered in this research report within 30 calendar days prior to the date of issue of this report; (2) will deal in or trade in the stock(s) covered in this research report 3 business days after the date of issue of this report; (3) serve as an officer of any of the Hong Kong listed companies covered in this report; and (4) have any financial interests in the Hong Kong listed companies covered in this report.

CMBIGM Ratings

BUY

: Stock with potential return of over 15% over next 12 months

HOLD

: Stock with potential return of +15% to -10% over next 12 months

SELL

: Stock with potential loss of over 10% over next 12 months

NOT RATED

: Stock is not rated by CMBIGM

OUTPERFORM OUTPERFORM MARKET-PERFORM UNDERPERFORM UNDERPERFORM

: Industry expected to outperform the relevant broad market benchmark over next 12 months

: Industry expected to perform in-line with the relevant broad market benchmark over next 12 months

: Industry expected to underperform the relevant broad market benchmark over next 12 months

CMB International Global Markets Limited

Address: 45/F, Champion Tower, 3 Garden Road, Hong Kong, Tel: (852) 3900 0888 Fax: (852) 3900 0800

CMB International Global Markets Limited (“CMBIGM”) is a wholly owned subsidiary of CMB International Capital Corporation Limited (a wholly owned subsidiary of China Merchants Bank)

Important Disclosures

There are risks involved in transacting in any securities. The information contained in this report may not be suitable for the purposes of all investors. CMBIGM does not provide individually tailored investment advice. This report has been prepared without regard to the individual investment objectives, financial position or special requirements. Past performance has no indication of future performance, and actual events may differ materially from that which is contained in the report. The value of, and returns from, any investments are uncertain and are not guaranteed and may fluctuate as a result of their dependence on the performance of underlying assets or other variable market factors. CMBIGM recommends that investors should independently evaluate particular investments and strategies, and encourages investors to consult with a professional financial advisor in order to make their own investment decisions.

This report or any information contained herein, has been prepared and distributed in Hong Kong by CMBIGM under its regulatory framework for the regulated activities licensed and regulated by the Securities and Futures Commission of Hong Kong. The report is solely for the purpose of supplying information to the clients of CMBIGM or its affiliate(s) to whom it is distributed. This report is not and should not be construed as an offer or solicitation to buy or sell any security or any interest in securities or enter into any transaction. Neither CMBIGM nor any of its affiliates, shareholders, agents, consultants, directors, officers or employees shall be liable for any loss, damage or expense whatsoever, whether direct or consequential, incurred in relying on the information contained in this report. Anyone making use of the information contained in this report does so entirely at their own risk.

The information and contents contained in this report are based on the analyses and interpretations of information believed to be publicly available and reliable. CMBIGM has exerted every effort in its capacity to ensure, but not to guarantee, their accuracy, completeness, timeliness or correctness. CMBIGM provides the information, advices and forecasts on an "AS IS" basis. The information and contents are subject to chan e without notice. CMBIGM may issue other publications having information and/ or conclusions different from this report. These publications reflect different assumption, point-of-view and analytica methods when compiling. CMBIGM may make investment decisions or take proprietary positions that are inconsistent with the recommendations or views in this report.

CMBIGM may have a position, make markets or act as principal or engage in transactions in securities of companies referred to in this report for itself and/or on behalf of its clients from time to time. Investors should assume that CMBIGM does or seeks to have investment banking or other business relationships with the companies in this report. As a result, recipients should be aware that CMBIGM may have a conflict of interest that could affect the objectivity of this report and CMBIGM will not assume any responsibility in respect thereof. This report is for the use of intended recipients only and this publication, may not be reproduced, reprinted, sold, redistributed, directly or indirectly, to any other person, published in whole or in part for any purpose without prior written consent of CMBIGM.

Additional information on recommended securities is available upon request. If there is any inconsistency between the Chinese and English versions of this Important Disclosure, the English version shall prevail.

For recipients of this document in the United Kingdom

This report has been provided only to persons (I)falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended from time to time)(“The Order”) or (II) are persons falling within Article 49(2) (a) to (d) (“High Net Worth Companies, Unincorporated Associations, etc.,) of the Order, and may not be provided to any other person without the prior written consent of CMBIGM.

For recipients of this document in the United States

CMBIGM is not a registered broker-dealer in the United States. As a result, CMBIGM is not subiect to US, rules regarding the preparation of research reports and the independence of research analysts. The research analyst who is primary responsible for the content of this research report is not registered or qualified as a research analyst with the Einancial Industry Regulatory Authority (“EINRA”). The analyst is not subiect to applicable restrictions under, EINRÀ, Rules intended to ensure that the analyst is not affected by potential conflicts of interest that could bear upon the reliability of the research report. This report is intended for distribution in the United States solely to "maior US institutional investors", as defined in Rule 15a-6 under the US. Securities Exchange Act of 1934, as amended, and may not be furnished to any other person in the United States. Each major US institutional investor that receives a copy of this report by its acceptance hereof represents and agrees that it shall not distribute or provide this report to any other person. Any U.S. recipient of this report wishing to effect any transaction to buy or sell securities based on the information provided in this report should do so only through a U.S.-registered broker-dealer.

For recipients of this document in Singapore

This report is distributed in Singapore by CMBI (Singapore) Pte. Limited (CMBISG) (Company Regn. No. 201731928D), an Exempt Financial Adviser as defined in the Financial Advisers Act (Cap. 110) of Singapore and regulated by the Monetary Authority of Singapore. CMBISG may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, as defined in the Securities and Futures Act (Cap. 289) of Singapore, CMBISG accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact CMBISG at +65 6350 4400 for matters arising from, or in connection with the report.